SF30_SPE2D224R00130008.PDF

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT

1. CONTRACT ID CODE

2. AMENDMENT/MODIFICATION NO.

See Block 14

4. REQUISITION/PURCHASE REQ. NO. 5. PROJECT NO. (If applicable)

6. ISSUED BY CODE SPE2D2 7. ADMINISTERED BY (If other than Item 6) CODE

8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)

CODE FACILITY CODE

SPE2D224R0013

X

2024 SEP 10

10A. MODIFICATION OF CONTRACT/ORDER NO.

10B. DATED (SEE ITEM 13)

11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of OffersX is extended, X is not extended.

or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

1 copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted;

Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:

12. ACCOUNTING AND APPROPRIATION DATA (If required)

A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO.

IN ITEM 10A.

B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc. ) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

E. IMPORTANT: Contractor is not, is required to sign this document and return copies to issuing office.

14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

15A NAME AND TITLE OF SIGNER (Type or print)

NSN 7540-01-152-8070

Previous edition unusable

STANDARD FORM 30 (REV. 10-83)

Prescribed by GSA FAR (48 CFR) 53.243

16B. UNITED STATES OF AMERICA15B. CONTRACTOR/OFFEROR

(Signature of Contracting Officer)(Signature of person authorized to sign)

16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)

(a) By completing Items 8 and 15, and returning

DLA TROOP SUPPORT

MEDICAL SUPPLY CHAIN FSGB

700 ROBBINS AVENUE

PHILADELPHIA PA 19111

15C. DATE SIGNED 16C. DATE SIGNED

D. OTHER (Specify type of modification and authority)

2025 MAR 13

3. EFFECTIVE DATE

See Attached Continuation Sheet(s).

(X)

CHECK ONE

9A. AMENDMENT OF SOLICITATION NO.

9B. DATED (SEE ITEM 11)

13. THIS APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS.

IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

CONTINUATION SHEET REFERENCE NO. OF DOCUMENT BEING CONTINUED: PAGE 2 OF 2 PAGES

SPE2D224R0013 - 0008

1. Language on page 46, paragraph 2, (a), a of the solicitation has been updated as follows:

From:

Tab A: Offeror's Completed, Signed, and Dated SF 1449 and all pages of the solicitation (1 through 94).

To:

Tab A: Offeror's Completed, Signed, and Dated SF 1449 and all pages of the solicitation (1 through 101).

2. Language on page 47, paragraph 1 of the solicitation has been updated as follows:

From:

Separate from this requirement, the offeror must complete FAR clause 52.215-6 on page 77 of the solicitation, including the chart “TABLETS, CAPSULES AND PILLS” on page 78-79 of the solicitation.

To:

Separate from this requirement, the offeror must complete FAR clause 52.215-6 on page 77 of the solicitation, including the chart “TABLETS, CAPSULES AND PILLS” on page 83-86 of the solicitation.

3. Language on page 47, paragraph e, i.,1, f of the solicitation has been updated as follows:

From:

Shall state that all entities identified in FAR clause 52.215-6 Place of Performance and in “TABLETS, CAPSULES AND PILLS” chart on page 78-79 are FDA current Good Manufacturing Practice (cGMP ) acceptable and have clearance by the FDA to manufacture under the specific NDA/ANDA/BLA.

To:

Shall state that all entities identified in FAR clause 52.215-6 Place of Performance and in “TABLETS, CAPSULES AND PILLS” chart on page 83-86 are FDA current Good Manufacturing Practice (cGMP ) acceptable and have clearance by the FDA to manufacture under the specific NDA/ANDA/BLA.

4. Language on page 48, paragraph ii, 1, f of the solicitation has been updated as follows:

From:

Shall state that all entities identified in FAR Clause 52.215-6 Place of Performance and in “TABLETS, CAPSULES AND PILLS” chart on page 78-79 are FDA cGMP acceptable and have clearance by the FDA to manufacture under the specific

NDA/ANDA/BLA.

To:

Shall state that all entities identified in FAR Clause 52.215-6 Place of Performance and in “TABLETS, CAPSULES AND PILLS” chart on page 83-86 are FDA cGMP acceptable and have clearance by the FDA to manufacture under the specific

NDA/ANDA/BLA.

5. Language on page 51, paragraph b, second subparagraph of the solicitation has been updated as follows:

From:

Tab A: Offeror's Proposed Prices. Offerors are required to provide pricing information for line items 0001-0006. For CLIN 0001 offers shall include pricing for 17,874-Potassium Chloride ER 10 MEQ Tablet-100 count bottle. For CLIN 0002 offers shall include pricing for 112,727-Potassium Chloride ER 10 MEQ Tablet-500 count bottle. For CLIN 0003 offers shall include pricing for 4,087 Potassium Chloride ER 10 MEQ Tablet-1,000 count bottle. For CLIN 0004 offers shall include pricing for 28,322 Potassium Chloride ER 20 MEQ Tablet-100 count bottle. For CLIN 0005 offers shall include pricing for 81,764-Potassium Chloride ER 20 MEQ Tablet-500 count bottle. For CLIN 0006 offers shall include pricing for 979 Potassium Chloride ER 20 MEQ Tablet-1,000 count bottle. The offeror’s proposed prices are to be expressed in dollars as a unit price per bottle.

To:

Tab A: Offeror's Proposed Prices. Offerors are required to provide pricing information for line items 0001-0004. For CLIN 0001 offers shall include pricing for 17,874-Potassium Chloride ER 10 MEQ Tablet-100 count bottle. For CLIN 0002 offers shall include pricing for 120,901-Potassium Chloride ER 10 MEQ Tablet-500 count bottle. For CLIN 0003 offers shall include pricing for 28,322 Potassium Chloride ER 20 MEQ Tablet-100 count bottle. For CLIN 0004 offers shall include pricing for 83,722-Potassium Chloride ER 20 MEQ Tablet-500 count bottle. The offeror’s proposed prices are to be expressed in dollars as a unit price per bottle.

6. Language on page 56, paragraph iv, second subparagraph of the solicitation has been updated as follows:

From:

Offerors are required to provide pricing information for line items 0001- 0006. The offeror’s proposed prices are to be expressed in dollars (USD) as a unit price per bottle.

To:

Offerors are required to provide pricing information for line items 0001- 0004. The offeror’s proposed prices are to be expressed in dollars (USD) as a unit price per bottle.

7. All other terms and conditions remain the same.